- NVAX, +30.80% as it rallied after the biotech announced it received a large 384m investment for its COVID-19 vaccine candidate and beat Earnings expectations.
- Technically we are in a strong uptrend - just broken out of its corrective move down. This is the type of stock which may take off further quite quickly - we could wait for a pullback (possibly at the old highs) or buy this breakout at the open market. Will depend on your risk appetite.
- Targets have been set based on the Pitchforks and Median Line Theory.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.